Loading company
Loading
Latest annual · FY2024
Millions- Free cash flow
- (5)
Latest quarter · Q2 FY2026
Millions- Total revenues
- 0
- Gross profit
- 0
- Operating income
- (2)
- Net income
- (2)
Harvard Apparatus Regenerative Technology, Inc. (HRGN) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | $704,000 | $430,000 | +63.7% | 10-K 2026-03-19 · proof |
| Gross profit | $58,000 | $160,000 | -63.8% | 10-K 2026-03-19 · proof |
| Operating income | -$6.9 million | -$7.7 million | 10-K 2026-03-19 · proof | |
| Net income | -$6.9 million | -$7.7 million | 10-K 2026-03-19 · proof | |
| Cash from operating activities | -$3.8 million | -$4.9 million | 10-K 2026-03-19 · proof | |
| Total assets | $2.7 million | $4.4 million | -39.7% | 10-K 2026-03-19 · proof |
| Total liabilities | $1.6 million | $1.2 million | +32.8% | 10-K 2026-03-19 · proof |
| Cash and cash equivalents | $1.4 million | $2.5 million | -45.6% | 10-K 2026-03-19 · proof |
- What was Harvard Apparatus Regenerative Technology, Inc. (HRGN)'s revenue in fiscal 2025?
- Harvard Apparatus Regenerative Technology, Inc. (HRGN) reported revenue of $704,000 for fiscal 2025 (the year ended Dec 31, 2025), against $430,000 the year before (+63.7%). Source: the 10-K filed with the SEC on Mar 19, 2026. SEC
- What was Harvard Apparatus Regenerative Technology, Inc. (HRGN)'s gross profit in fiscal 2025?
- Harvard Apparatus Regenerative Technology, Inc. (HRGN) reported gross profit of $58,000 for fiscal 2025 (the year ended Dec 31, 2025), against $160,000 the year before (-63.8%). Source: the 10-K filed with the SEC on Mar 19, 2026. SEC
- What was Harvard Apparatus Regenerative Technology, Inc. (HRGN)'s operating income in fiscal 2025?
- Harvard Apparatus Regenerative Technology, Inc. (HRGN) reported operating income of -$6.9 million for fiscal 2025 (the year ended Dec 31, 2025), against -$7.7 million the year before. Source: the 10-K filed with the SEC on Mar 19, 2026. SEC
- What was Harvard Apparatus Regenerative Technology, Inc. (HRGN)'s net income in fiscal 2025?
- Harvard Apparatus Regenerative Technology, Inc. (HRGN) reported net income of -$6.9 million for fiscal 2025 (the year ended Dec 31, 2025), against -$7.7 million the year before. Source: the 10-K filed with the SEC on Mar 19, 2026. SEC
- What was Harvard Apparatus Regenerative Technology, Inc. (HRGN)'s cash from operating activities in fiscal 2025?
- Harvard Apparatus Regenerative Technology, Inc. (HRGN) reported cash from operating activities of -$3.8 million for fiscal 2025 (the year ended Dec 31, 2025), against -$4.9 million the year before. Source: the 10-K filed with the SEC on Mar 19, 2026. SEC
- What are Harvard Apparatus Regenerative Technology, Inc. (HRGN)'s total assets?
- As of Dec 31, 2025, Harvard Apparatus Regenerative Technology, Inc. (HRGN) reported total assets of $2.7 million, against $4.4 million a year earlier (-39.7%). Source: the 10-K filed with the SEC on Mar 19, 2026. SEC
- What are Harvard Apparatus Regenerative Technology, Inc. (HRGN)'s total liabilities?
- As of Dec 31, 2025, Harvard Apparatus Regenerative Technology, Inc. (HRGN) reported total liabilities of $1.6 million, against $1.2 million a year earlier (+32.8%). Source: the 10-K filed with the SEC on Mar 19, 2026. SEC
- What are Harvard Apparatus Regenerative Technology, Inc. (HRGN)'s cash and cash equivalents?
- As of Dec 31, 2025, Harvard Apparatus Regenerative Technology, Inc. (HRGN) reported cash and cash equivalents of $1.4 million, against $2.5 million a year earlier (-45.6%). Source: the 10-K filed with the SEC on Mar 19, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:HRGN&period_type=annual&limit=5"Information only, not investment advice.